PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
Phase 1
21
about 4.3 years
18+
Male only
1 site in CA
What this study is about
This trial is testing a treatment with autologous anti-PSCA-CAR-T cells, possibly plus radiation therapy, to treat prostate cancer that has spread. The goal is to determine the safe dose and side effects of this new treatment approach for men whose cancer hasn't responded to standard treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- 2.Receive External Beam Radiation Therapy
- 3.Undergo Biopsy
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of adverse events
Secondary: Overall survival, Progression-free survival, Serum cytokine profile
biopsy, diagnostic, imaging, radiation, therapy
Oncology